1[1]Beral V,Million Women Study Collaborators,Bull D,et al.Ovarian cancer and hormone replacement therapy in the Million Women Study[J].Lancet,2007,369(9574):1703-1710. 被引量：1
2[2]Reya T,Morrison SJ,Clarke MF,et al.Stem cells,cancer,and cancer stem cells[J].Nature,2001,414(6859):105-111. 被引量：1
3[3]Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J].Nat Med,1997,3(7):730-737. 被引量：1
4[4]Ponti D,Costa A,Zaffaroni N,et al.Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties[J].Cancer Res,2005,65(13):5506-5511. 被引量：1
5[5]Singh SK,Hawkins C,Clarke ID,et al.Identification of human brain tumour initiating cells[J].Nature,2004,432(7015):396-401. 被引量：1
6[6]Kim CF,Jackson EL,Woolfenden AE,et al.Identification of bronchioalveolar stem cells in normal lung and lung cancer[J].Cell,2005,121(6):823-835. 被引量：1
7[7]Li C,Heidt DG,Dalerba P,et al.Identification of pancroatie cancer stem cells[J].Cancer Res,2007,67(3):1030-1037. 被引量：1
8[8]Bapat SA,Mali AM,Koppikar CB,et al.Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer[J].Cancer Res,2005,65(8):3025-3029. 被引量：1
9[9]Szotek PP,Pieretti-Vanmarcke R,Masiakos IT,et al.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness[J].Proc Natl Acad Sci U S A,2006,103(30):11154-11159. 被引量：1
3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007.CA Cancer J Clin,2007,57(1):43-66. 被引量：1
4Gaddueei A,Cosio S,Zola P,et al.Surveillance procedures for patients treated for epithelial ovarian cancer:a review of the literature.Int J Gyneeol Cancer,2007,17(1):21-31. 被引量：1
5Renehan AG,Tyson M,Egger M,et al.Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies.Lancet,2008,371(9612):569-578. 被引量：1
6Heintz AP,Odicino F,Maisonneuve P,et al.Carcinoma of the ovary.Int J Gynaeeol Obstet,2003,83 Suppl 1:135-166. 被引量：1
7Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.Cancer Res,2003,63(13):3695-3700. 被引量：1
8Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol,2008,108(2):402-408. 被引量：1
9Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol,2009,112(1):40-46. 被引量：1
10Foster T,Brown TM,Chang J,et al.A review of the current evidence for naaintenanee therapy in ovarian cancer.Gynecol Oncol,2009,115(2):290-301. 被引量：1
